Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
GSK reports promising phase III trial outcomes for Nucala (mepolizumab) in treating COPD
Latest Hotspot
3 min read
GSK reports promising phase III trial outcomes for Nucala (mepolizumab) in treating COPD
10 September 2024
GSK plc (LSE/NYSE: GSK) released encouraging top-line outcomes from MATINEE in adult patients suffering from chronic obstructive pulmonary disease (COPD).
Read →
Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application
Hot Spotlight
6 min read
Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application
10 September 2024
Competing in the $40 Billion Alopecia Areata Market: Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application.
Read →
Ventyx Biosciences Begins Phase 2a Trial Dosing of VTX3232 for Early Parkinson’s Disease
Latest Hotspot
3 min read
Ventyx Biosciences Begins Phase 2a Trial Dosing of VTX3232 for Early Parkinson’s Disease
10 September 2024
Ventyx Biosciences announced that the initial patient has been administered a dose in a Phase 2a study of VTX3232 for individuals with early-stage Parkinson’s disease.
Read →
Cytonics Finishes Phase 1 Enrollment for CYT-108 Study in Knee Osteoarthritis
Latest Hotspot
3 min read
Cytonics Finishes Phase 1 Enrollment for CYT-108 Study in Knee Osteoarthritis
10 September 2024
Cytonics Completes Phase 1 Enrollment for Study on CYT-108, a New Protease Inhibitor, in Knee Osteoarthritis Patients.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 10
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 10
10 September 2024
Sep 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Huonslab Reports Positive In Vivo PK Results for Trastuzumab/HyDIFFUZETM vs. Standard Trastuzumab and rHuPH20 Co-formulation
Latest Hotspot
2 min read
Huonslab Reports Positive In Vivo PK Results for Trastuzumab/HyDIFFUZETM vs. Standard Trastuzumab and rHuPH20 Co-formulation
10 September 2024
Huonslab Reveals Favorable In Vivo PK Study Outcomes for Trastuzumab/HyDIFFUZETM vs. Commercial rHuPH20 and Trastuzumab Co-formulation.
Read →
NextPoint Therapeutics Unveils NPX372, a New T Cell Engager Targeting B7-H7 in Solid Tumors
Latest Hotspot
3 min read
NextPoint Therapeutics Unveils NPX372, a New T Cell Engager Targeting B7-H7 in Solid Tumors
10 September 2024
NextPoint Therapeutics Reveals NPX372, a Novel Drug Targeting B7-H7 in Solid Tumors, as New T Cell Engager.
Read →
Medigene's MDG1015, a Third-Generation T Cell Therapy, Wins FDA Approval for IND Trials in Solid Tumors
Latest Hotspot
4 min read
Medigene's MDG1015, a Third-Generation T Cell Therapy, Wins FDA Approval for IND Trials in Solid Tumors
10 September 2024
Medigene Gets U.S. FDA Approval for IND of MDG1015, a Novel Third Gen T Cell Therapy Targeting Various Solid Tumors.
Read →
Boehringer Ingelheim Advances Promising Geographic Atrophy Therapy Following Positive Phase I Results
Latest Hotspot
4 min read
Boehringer Ingelheim Advances Promising Geographic Atrophy Therapy Following Positive Phase I Results
9 September 2024
Boehringer Ingelheim reveals intention to progress a promising new therapy for Geographic Atrophy, inspired by favorable Phase I outcomes.
Read →
"Overturning" the B7H3 Target: Can Its Potential be Transformed with ADC Drugs?
Hot Spotlight
12 min read
"Overturning" the B7H3 Target: Can Its Potential be Transformed with ADC Drugs?
9 September 2024
B7-H3 (also known as CD276) is a type I transmembrane glycoprotein and a member of the B7 family.
Read →
Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction: A Fixed Dose Study
Latest Hotspot
3 min read
Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction: A Fixed Dose Study
9 September 2024
In a pioneering fixed dose study, weekly insulin efsitora alfa achieves A1C reduction comparable to that of daily insulin.
Read →
Crestone Releases Encouraging Phase 2 Trial Results for CRS3123 in Treating C. Difficile Infections (CDI)
Latest Hotspot
3 min read
Crestone Releases Encouraging Phase 2 Trial Results for CRS3123 in Treating C. Difficile Infections (CDI)
9 September 2024
Crestone, Inc. ("Crestone") announced promising initial results from its Phase 2 clinical trial of CRS3123 in patients with Clostridioides difficile infection (CDI).
Read →